Cargando…
Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255291/ https://www.ncbi.nlm.nih.gov/pubmed/34258531 http://dx.doi.org/10.1002/iju5.12291 |
| _version_ | 1783717875901530112 |
|---|---|
| author | Matsumoto, Takashi Shiota, Masaki |
| author_facet | Matsumoto, Takashi Shiota, Masaki |
| author_sort | Matsumoto, Takashi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8255291 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82552912021-07-12 Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification Matsumoto, Takashi Shiota, Masaki IJU Case Rep Editorial Comment John Wiley and Sons Inc. 2021-05-04 /pmc/articles/PMC8255291/ /pubmed/34258531 http://dx.doi.org/10.1002/iju5.12291 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Comment Matsumoto, Takashi Shiota, Masaki Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification |
| title | Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification |
| title_full | Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification |
| title_fullStr | Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification |
| title_full_unstemmed | Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification |
| title_short | Editorial Comment to Prominent response to platinum‐based chemotherapy in a patient with BRCA2 mutant‐neuroendocrine prostate cancer and MDM2 amplification |
| title_sort | editorial comment to prominent response to platinum‐based chemotherapy in a patient with brca2 mutant‐neuroendocrine prostate cancer and mdm2 amplification |
| topic | Editorial Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255291/ https://www.ncbi.nlm.nih.gov/pubmed/34258531 http://dx.doi.org/10.1002/iju5.12291 |
| work_keys_str_mv | AT matsumototakashi editorialcommenttoprominentresponsetoplatinumbasedchemotherapyinapatientwithbrca2mutantneuroendocrineprostatecancerandmdm2amplification AT shiotamasaki editorialcommenttoprominentresponsetoplatinumbasedchemotherapyinapatientwithbrca2mutantneuroendocrineprostatecancerandmdm2amplification |